Prospective Study Open Access
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Aug 6, 2024; 12(22): 5042-5050
Published online Aug 6, 2024. doi: 10.12998/wjcc.v12.i22.5042
Effectiveness of onsite and online education in enhancing knowledge and use of human immunodeficiency virus pre- and post-exposure prophylaxis
Ying Shao, Li-Jun Sun, Hong-Wei Zhang, An Liu, Xi Wang, Jian-Wei Li, Jiang-Zhu Ye, Yue Gao, Zhang-Li Wang, Zai-Cun Li, Clinic of Center for Infection, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China
Mei Zhang, Tong Zhang, Department of Infectious Diseases and Medical Immunology, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China
Li-Jun Sun, Chinese Association of STD and AIDS Prevention and Control, Beijing 100050, China
Ruo-Lei Xin, Institute of STD/AIDS Prevention and Control, Beijing Center for Disease Prevention and Control, Beijing 100013, China
ORCID number: Hong-Wei Zhang (0000-0002-1280-3332); Zai-Cun Li (0009-0005-0773-3316); Tong Zhang (0000-0003-0179-8555).
Co-first authors: Ying Shao and Mei Zhang.
Co-corresponding authors: Zai-Cun Li and Tong Zhang.
Author contributions: Shao Y contributed to the methodology and writing of the original draft; Zhang M contributed to validation and writing of the original draft; Sun LJ contributed to funding acquisition and writing, reviewing, and editing; Zhang HW supervised the project and contributed to the writing of the original draft; Liu A curated the data and contributed to writing, reviewing, and editing; Wang X, Xin RL, Li JW, Ye JZ, Gao Y, and Wang ZL contributed to resourcing, writing, reviewing, and editing; Li ZC contributed to conceptualization and writing, reviewing, and editing; Zhang T managed the project administration and contributed to writing, reviewing, and editing; All authors provided comments on previous versions of the manuscript and approved the final version.
Institutional review board statement: This study received ethical approval from the ethics committee of Beijing Youan Hospital, Capital Medical University [No. (2021) 078], and the research was implemented in strict conformity with the guidelines outlined in the Declaration of Helsinki.
Clinical trial registration statement: The registration number for the study was ChiCTR2100048080.
Informed consent statement: The determination of patients’ capacity to provide written informed consent was based on their thorough understanding of time, location, and personal identity, in addition to their ability to comprehend the explanations provided by the investigator.
Conflict-of-interest statement: All the authors declare that they have no conflict of interest.
Data sharing statement: Datasets utilized and/or analyzed during this investigation, including the study protocol, participant data, and statistical analysis plan, which have been redacted, are accessible from the corresponding authors upon valid request.
CONSORT 2010 statement: The authors have read the CONSORT 2010 statement, and the manuscript was prepared and revised according to the CONSORT 2010 statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tong Zhang, MD, Professor, Department of Infectious Diseases and Medical Immunology, Beijing Youan Hospital, Capital Medical University, No. 8 Xitoutiao, Youanmenwai, Fengtai District, Beijing 100069, China. zt_doc@ccmu.edu.cn
Received: January 30, 2024
Revised: May 13, 2024
Accepted: June 11, 2024
Published online: August 6, 2024
Processing time: 153 Days and 17.8 Hours

Abstract
BACKGROUND

Enhancing awareness and use of pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) is vital to curb human immunodeficiency virus (HIV) spread. High-risk behaviors prevalent among sexually transmitted infection clinic outpatients underscore the need for increased PrEP/PEP education in this group.

AIM

To investigate the effects of both onsite and online health education on the knowledge of, and willingness to use, PrEP and PEP among individuals receiving PEP services.

METHODS

Participants were drawn from a cohort study on PEP service intervention at an STD/AIDS outpatient clinic in designated HIV/AIDS hospitals in Beijing, conducted from January 1 to June 30, 2022. Health education was provided both onsite and online during follow-up. Surveys assessing knowledge of, and willingness to use, PrEP/PEP were administered at baseline and again at 24 wk post-intervention.

RESULTS

A total of 112 participants were enrolled in the study; 105 completed the follow-up at week 24. The percentage of participants with adequate knowledge of, and willingness to use, PrEP significantly increased from 65.2% and 69.6% at baseline to 83.8% and 82.9% at the end of the intervention (both P < 0.05). Similarly, those with adequate knowledge of, and willingness to use, PEP increased from 74.1% and 77.7% at baseline to 92.4% and 89.5% at week 24 (P < 0.05). Being between 31 years and 40 years of age, having a postgraduate degree or higher, and reporting a monthly expenditure of RMB 5000 or more were found to be significantly associated with knowledge of PrEP and PEP (both P < 0.05).

CONCLUSION

The findings show that both onsite and online health education significantly improved the knowledge of, and increased willingness to use, PrEP and PEP in individuals utilizing PEP services.

Key Words: Human immunodeficiency virus, Pre-exposure prophylaxis, Post-exposure prophylaxis, Health education, Intervention

Core Tip: The study aimed to assess the impact of onsite and online health education on the awareness and adoption of pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) by PEP service users at a Beijing STD/AIDS clinic. Between January and June 2022, 112 participants were enrolled, and 105 completed the study. Education efforts led to a significant increase in the knowledge of and willingness to use PrEP and PEP, with adequate understanding of PrEP increasing from 65.2% to 83.8%, and PEP from 74.1% to 92.4%. The study concluded that both education methods effectively improved PrEP and PEP uptake by high-risk individuals.



INTRODUCTION

The epidemic of human immunodeficiency virus (HIV) remains a major global public health challenge. In 2021, an estimated 38.4 (33.9–43.8) million people were living with HIV, with approximately 1.5 million new infections and 650000 acquired immunodeficiency syndrome (AIDS)-related deaths reported[1]. By October 2020, 1.045 million people were reported living with HIV/AIDS across China[2]. In addition to scaling up testing and antiretroviral therapy, HIV prevention is a crucial component of the strategy to end HIV/AIDS as a public health threat by 2030[3].

Pre-exposure prophylaxis (PrEP) is a promising strategy for HIV prevention and involves the use of antiretroviral drugs by HIV-uninfected individuals to prevent infection. PrEP was first approved for HIV prevention by the US Food and Drug Administration in 2012 and has been recommended by the World Health Organization for individuals at high risk of HIV infection[4]. PrEP has been shown to significantly reduce the risk of HIV infection in HIV-negative individuals who adhere to the regimen[5-7]. Post-exposure prophylaxis (PEP) consists of a short-term course of HIV medicine taken soon after a potential exposure to HIV. If initiated promptly, within 72 h after exposure, PEP is effective in preventing HIV infection[8-10] and has become the standard of care following occupational and sexual exposure to the virus[11]. According to recent studies, the rate of PrEP use was 9.2%-13.8%, and the rate of PEP use was 8.7%-9.2%[12-14].

As there is no available HIV vaccine, these two biomedical interventions, based on antiretroviral therapy, are considered critical for HIV prevention. High levels of knowledge, acceptability, and use of PrEP and PEP are necessary to reduce HIV transmission within the general population. Outpatients visiting sexually transmitted infection clinics often engage in behaviors associated with a high risk of HIV infection. The aim of this study was to assess the level of knowledge and willingness to use PrEP and PEP, as well as the impact of health education on the use of PrEP and PEP by patients receiving PEP services.

MATERIALS AND METHODS
Cohort study design

The participants came from a cohort enrolled in the PEP study at a STD/AIDS clinic within one of the HIV/AIDS designated hospitals in Beijing, from January 1st to June 30th, 2022. All participants were on PEP and were provided with the co-formulated regimen of bictegravir/emtricitabine/tenofovir alafenamide, along with health education on both PrEP and PEP. This study was approved by the ethics committee of Beijing Youan Hospital, Capital Medical University. Informed consent was obtained from all participants. A total of 112 participants were enrolled at baseline.

Onsite and online health education

Nurses, who were trained to provide information about PrEP and PEP, conducted health education onsite at the baseline, week 2, and week 4 visits. The information provided details on: “What are PrEP and PEP? What is on-demand PrEP? How can I start PrEP? How long does it take for PrEP to become effective? What is the maximum allowable delay in starting PEP? How long should the PEP regimen be taken? What behaviors increase the risk of contracting HIV? Are there any side effects?” This information was available to the participants on the WeChat and the Haodaifu Websites. If the participants had any questions, they could communicate with physicians online. For example, a participant inquired on the web about the steps to take after potential exposure to HIV through anal sex in the third week of the PEP course. The participant was advised to complete the remaining PEP medication, as this protocol aligns with the on-demand PrEP strategy.

Data collection and variable definition

A questionnaire was administered to assess the knowledge of and willingness to use PrEP and PEP among outpatients receiving PEP services at baseline and at week 24. Demographic information collected included age, sex, education level, sexual orientation, history of drug use, and history of STD infections. The questionnaire was derived and from previous literature and adapted to fit our study design[15-17]. It comprised 15 items on knowledge about PrEP and another 15 on PEP, Knowledge. Questions were scored equitably, with one point awarded for each correct response. A good knowledge level was defined as correctly answering more than 70% of the questions and scoring less than 70% correct answers was considered a poor knowledge level.

Statistical analysis

Data were analyzed with IBM SPSS 17.0 for Windows (SPSS Inc., Chicago, IL, United States). Continuous variables were reported as medians and interquartile range. Categorical variables were reported as counts and percentages. Group comparisons were made using the χ2 test. A P value of < 0.05 was indicated statistical significance. Factors associated with knowledge of PrEP and PEP were determined by univariate and multivariate logistic regression.

RESULTS
Demographic characteristics

A total of 112 participants completed the survey at baseline. The demographic characteristics of the participants are shown in Table 1. The majority (97.3%) were men, and 83.0% were between 20 years and 40 years of age. Approximately four-fifths (85.7%) had attained at least a college education and about half (51.9%) reported a monthly income of 5000 RMB or more. The majority identified as homosexual (61.6%), had no history of STD infection (85.7%), and no history of drug use (91.1%). At the 24-wk follow-up, only 105 participants responded and completed the survey.

Table 1 Baseline demographic and sexual behavior characteristics of participants in Beijing.
Variables
Frequency, n = 112
%
Age in yr
    20-304943.7
    31-404439.3
    41-501513.4
    51-6043.6
Sex
    Male10997.3
    Female32.7
Education level
    High school or below1614.3
    College and undergraduate6860.7
    Postgraduate or above2825
Monthly expenditure in RMB
    Less than 100087.5
    1000-29992522.6
    3000-49992017
    5000 and above5951.9
Sexual orientation
    Heterosexual2925.9
    Homosexual6961.6
    Bisexual 1412.5
History of STD
    Yes1614.3
    No9685.7
History of drug use
    Yes108.9
    No10291.1
Knowledge and willingness to use PrEP

At baseline, 65.2% of participants had a good knowledge of PrEP, and 69.6% were willing to use PrEP. At. Following the health education intervention, at week 24, the percentages of participants with good knowledge and those willing to use PrEP had increased to 83.8% and 82.9%, respectively (both P < 0.05) (Table 2).

Table 2 Comparison of knowledge of and willingness to use human immunodeficiency virus pre-exposure prophylaxis before and after intervention.
Variable
Before intervention
After intervention
χ²
P value
n = 112, n (%)
n = 105, n (%)
Knowledge level of PrEP8.8460.003
    Good73 (65.2)88 (83.8)
    Poor39 (34.8)17 (16.2)
Willingness to use PrEP        4.5560.033
    Yes78 (69.6)87 (82.9)        
    No34 (30.4)18 (17.1)        
Knowledge and willingness to use PEP

At baseline, 74.1% of participants had good knowledge of PEP, and 77.7% were willing to use PEP. After the health education intervention, at week 24, the percentages of participants with good knowledge and those willing to use PEP had increased to 92.4% and 89.5%, respectively (both P < 0.05) (Table 3).

Table 3 Comparison of knowledge of and willingness to use human immunodeficiency virus post-exposure prophylaxis before and after intervention.
Variable
Before intervention
After intervention
χ²
P value
n = 112, n (%)
n =105, n (%)
Knowledge level of PEP11.5740.001
    Good83 (74.1)97 (92.4)
    Poor29 (25.9)8 (7.6)
Willingness to use PEP4.6340.031
    Yes87 (77.7)94 (89.5)
    No25 (22.3)11 (10.5)
Factors associated with knowledge of PEP and PrEP

As knowledge of PrEP and use of PEP are positively correlated with the use of PrEP and PEP[18], we assessed factors related to the knowledge of PrEP and PEP. The results of univariate and multivariate logistic regression are shown in Tables 4 and 5. Table 4 details findings regarding the knowledge of PrEP and Table 5 details findings regarding the knowledge of PEP.

Table 4 Factors associated with knowledge of pre-exposure prophylaxis.
Parameters
OR (95%CI)
P value
AOR (95%CI)
P value
Age in yr
    20-30Reference category
    31-400.326 (0.114, 0.929)0.036a0.268 (0.088, 0.817)0.021a
    41-500.147 (0.018, 1.221)0.1470.335 (0.082, 1.375)0.129
    51-602.062 (0.266, 16.004)0.4891.779 (0.303, 10.430)0.523
Sex
    MaleReference category
    Female4.253 (0.252, 71.662)0.5501.938 (0.128, 29.374)0.633
Education level
    High school or belowReference category
    College and undergraduate0.920 (0.191, 4.432)0.9170.325 (0.089, 1.181)0.088
    Postgraduate or above0.131 (0.023, 0.757)0.023a0.196 (0.044, 0.873)0.032a
Monthly expenditure in RMB
    Less than 1000Reference category
    1000-29990.706 (0.170, 2.923)0.6310.511 (0.085, 3.086)0.464
    3000-49990.447 (0.119, 1.669)0.2310.747 (0.121, 4.628)0.754
    5000 and above0.126 (0.019, 0.827)0.031a0.142 (0.024, 0.850)0.035a
Sexual orientation
    HeterosexualReference category
    Homosexual0.650 (0.197, 2.138)0.4780.986 (0.324, 3.006)0.981
    Bisexual 1.625 (0.326, 8.095)0.5531.785 (0.223, 14.275)0.585
History of STD
    YesReference category
    No1.445 (0.255, 8.205)0.6781.027 (0.259, 4.075)0.970
History of drug use
    YesReference category
    No0.540 (0.104, 2.798)0.4630.769 (0.121, 4.870)0.780
Table 5 Factors associated with knowledge of post-exposure prophylaxis.
Factors
OR (95%CI)
P value
AOR (95%CI)
P value
Age in yr
    20-30Reference category
    31-400.210 (0.045, 0.983)0.047a0.167 (0.033, 0.842)0.030a
    41-500.671 (0.143, 3.151)0.6130.886 (0.212, 3.708)0.869
    51-601.857 (0.168, 20.511)0.6151.147 (0.365, 3.601)0.814
Sex
    MaleReference category
    Female11.940 (0.523, 272.777)0.12010.813 (0.460, 254.122)0.139
Education level
    High school or belowReference category
    College and undergraduate0.591 (0.126, 2.781)0.5060.564 (0.127, 2.499)0.451
    Postgraduate or above0.045 (0.003, 0.678)0.025a0.103 (0.021, 0.513)0.005a
Monthly expenditure in RMB
    Less than 1000Reference category
    1000-29990.394 (0.055, 2.815)0.3530.435 (0.095, 1.996)0.435
    3000-49990.421 (0.070, 2.550)0.3470.473 (0.147, 1.522)0.209
    5000 and above0.101 (0.016, 0.654)0.016a0.140 (0.028, 0.690)0.017a
Sexual orientation
    HeterosexualReference category
    Homosexual0.424 (0.056, 3.215)0.2620.460 (0.063, 3.356)0.444
    Bisexual1.815 (0.366, 8.996)0.4621.487 (0.187, 11.808)0.708
History of STD
    YesReference category
    No3.264 (0.361, 29.482)0.2922.221 (0.260, 18.957)0.466
History of drug use
    YesReference category
    No0.832 (0.122, 5.656)0.8510.804 (0.122, 5.308)0.821

Individuals between 31 years and 40 years of age demonstrated a significant increase in knowledge of PrEP compared with those younger than 30 years of age (AOR 0.268; 95%CI: 0.088-0.817). In addition, a postgraduate degree or higher (AOR 0.196; 95%CI: 0.044-0.873) and reporting a monthly expenditure of RMB 5000 or more (AOR 0.142; 95%CI: 0.024-0.850) were also linked to greater knowledge of PrEP.

Similar patterns were observed for PEP, and several factors were significantly associated with reported knowledge (Table 5). Being between 31 years and 40 years of age (AOR 0.167; 95%CI: 0.033-0.842), having a postgraduate degree or higher (AOR 0.103; 95%CI: 0.021-0.513), and reporting a monthly expenditure of RMB 5000 or more (AOR 0.140; 95%CI: 0.028-0.690) were associated with increased knowledge of PEP.

DISCUSSION

The outcomes of this study underscore the significant impact that both onsite and online health education have on increasing the knowledge of individuals regarding PrEP and PEP. Face-to-face interaction with participants allowed for a deeper understanding of the complexities of PrEP and PEP[19,20], and the flexibility of an online platform facilitated convenient access to information and communication with healthcare providers[20,21]. The study findings revealed an increase in the participants’ knowledge from a baseline of 65.2% and 74.1% to 84.1% and 92.5% at week 24 for PrEP and PEP, respectively. This highlights the importance of incorporating both onsite and online health education to improve knowledge acquisition for PrEP and PEP.

Despite the proven effectiveness of PrEP and PEP in preventing HIV infection in high-risk populations[5,22], their implementation in China has been less than optimal[23]. Our study found that the initial willingness to use PrEP and PEP was 69.6% and 77.7%, respectively, which is consistent with recent studies in China[24,25]. Following the health education interventions, there was a notable improvement in the willingness to use these preventive measures. Thus, it is evident that both onsite and online health education have a crucial role in promoting the acceptance of PrEP and PEP by those at high risk for HIV.

Moreover, our study indicates that participants who experienced PEP services gained a better understanding of the safety and tolerability of the medications used in HIV prevention. This understanding is instrumental in alleviating concerns about the adverse reactions associated with these medications, thereby facilitating the uptake of PrEP and PEP. Knowing that the side effects are manageable may decrease the hesitancy of users to initiate these preventive measures and enhance their confidence in the preventive interventions.

The study results show that being between 31 years and 40 years of age, having a postgraduate degree or higher, and reporting a monthly expenditure of RMB 5000 or more, were significantly associated with knowledge of PrEP and PEP. Considering our findings that young people between 31 years and 40 years of age had better PrEP and PEP knowledge, there appears to be a disparity in knowledge linked to age[26,27]. Previous studies have shown that high income and a high education level were associated with high HIV knowledge[28,29]. High income and a high education level have also been associated with having knowledge about PrEP and PEP[30-33]. These findings are consistent with our study results. Generally, income and expenditure are balanced, with higher expenditure indicating higher income.

We must some study limitations. Firstly, being a single-center study with a relatively small sample size may have affected the generalizability of our findings. Secondly, the study did not explore differences in the impact of online vs physical health education for PrEP/PEP, as both approaches were used for the same participants. Thirdly, the potential for selection bias in participant recruitment could have affected the universality of our results. Future multicenter studies across diverse regions and backgrounds with larger sample sizes are needed to increase the representativeness of the study and would be able explore the differences between online and physical health education for PrEP/PEP.

In the dissemination of PrEP and PEP strategies, a variety of educational channels and strategies should be considered. These include, but are not limited to, onsite education, online learning, community support, and the active engagement of healthcare professionals. Educational programs that address different cultural and societal contexts may prove more effective. For example, targeting younger populations might benefit from the use of modern technological methods such as social media and mobile applications to disseminate knowledge and services related to PrEP and PEP[34,35].

Finally, future studies should explore the long-term effects of different types of health education on PrEP and PEP knowledge and willingness to use these medications and to investigate how these methods might vary in impact in different populations. Through this research, we can gain a better understanding of how to effectively promote PrEP and PEP in high-risk populations and reduce HIV transmission.

CONCLUSION

In summary, knowledge of and willingness to use PrEP and PEP significantly improved after health educational intervention. Onsite and online health education need to be a priority for improving HIV prevention and control in HIV high-risk populations.

Footnotes

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Medicine, general and internal

Country of origin: China

Peer-review report’s classification

Scientific Quality: Grade B

Novelty: Grade B

Creativity or Innovation: Grade A

Scientific Significance: Grade B

P-Reviewer: Ajijola L, United States S-Editor: Gong ZM L-Editor: Filipodia P-Editor: Che XX

References
1.  Murray TH. Field notes. The light that endures. Remembering John Arras. Hastings Cent Rep. 2015;45:insidefrontcover.  [PubMed]  [DOI]  [Cited in This Article: ]  [Reference Citation Analysis (0)]
2.  Xu JJ, Han MJ, Jiang YJ, Ding HB, Li X, Han XX, Lv F, Chen QF, Zhang ZN, Cui HL, Geng WQ, Zhang J, Wang Q, Kang J, Li XL, Sun H, Fu YJ, An MH, Hu QH, Chu ZX, Liu YJ, Shang H. Prevention and control of HIV/AIDS in China: lessons from the past three decades. Chin Med J (Engl). 2021;134:2799-2809.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 21]  [Cited by in F6Publishing: 22]  [Article Influence: 7.3]  [Reference Citation Analysis (0)]
3.  Poku NK. HIV Prevention: The Key to Ending AIDS by 2030. Open AIDS J. 2016;10:65-77.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 12]  [Cited by in F6Publishing: 12]  [Article Influence: 1.5]  [Reference Citation Analysis (0)]
4.  World Health Organization  Guidance on Pre-Exposure Oral Prophylaxis (PrEP) for Serodiscordant Couples, Men and Transgender Women Who Have Sex with Men at High Risk of HIV: Recommendations for Use in the Context of Demonstration Projects. edn. Geneva; 2012. Available from: http://apps.who.int/iris/bitstream/handle/10665/75188/9789241503884_eng.pdf;jsessionid=2A06592CE3248338EA19F659C6B12432?sequence=1.  [PubMed]  [DOI]  [Cited in This Article: ]
5.  Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O'Reilly KR, Koechlin FM, Rodolph M, Hodges-Mameletzis I, Grant RM. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;30:1973-1983.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 659]  [Cited by in F6Publishing: 653]  [Article Influence: 81.6]  [Reference Citation Analysis (0)]
6.  Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, Tremblay C, Le Gall JM, Cua E, Pasquet A, Raffi F, Pintado C, Chidiac C, Chas J, Charbonneau P, Delaugerre C, Suzan-Monti M, Loze B, Fonsart J, Peytavin G, Cheret A, Timsit J, Girard G, Lorente N, Préau M, Rooney JF, Wainberg MA, Thompson D, Rozenbaum W, Doré V, Marchand L, Simon MC, Etien N, Aboulker JP, Meyer L, Delfraissy JF; ANRS IPERGAY Study Group. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med. 2015;373:2237-2246.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1078]  [Cited by in F6Publishing: 1145]  [Article Influence: 127.2]  [Reference Citation Analysis (0)]
7.  Huang X, Hou J, Song A, Liu X, Yang X, Xu J, Zhang J, Hu Q, Chen H, Chen Y, Meyers K, Wu H. Efficacy and Safety of Oral TDF-Based Pre-exposure Prophylaxis for Men Who Have Sex With Men: A Systematic Review and Meta-Analysis. Front Pharmacol. 2018;9:799.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 33]  [Cited by in F6Publishing: 38]  [Article Influence: 6.3]  [Reference Citation Analysis (0)]
8.  Joyce MP, Kuhar D, Brooks JT. Notes from the field: occupationally acquired HIV infection among health care workers - United States, 1985-2013. MMWR Morb Mortal Wkly Rep. 2015;63:1245-1246.  [PubMed]  [DOI]  [Cited in This Article: ]
9.  Henderson DK. Postexposure treatment of HIV--taking some risks for safety's sake. N Engl J Med. 1997;337:1542-1543.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 16]  [Cited by in F6Publishing: 16]  [Article Influence: 0.6]  [Reference Citation Analysis (0)]
10.  Ford N, Shubber Z, Calmy A, Irvine C, Rapparini C, Ajose O, Beanland RL, Vitoria M, Doherty M, Mayer KH. Choice of antiretroviral drugs for postexposure prophylaxis for adults and adolescents: a systematic review. Clin Infect Dis. 2015;60 Suppl 3:S170-S176.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 31]  [Cited by in F6Publishing: 32]  [Article Influence: 4.0]  [Reference Citation Analysis (0)]
11.  Ford N, Mayer KH; World Health Organization Postexposure Prophylaxis Guideline Development Group. World Health Organization Guidelines on Postexposure Prophylaxis for HIV: Recommendations for a Public Health Approach. Clin Infect Dis. 2015;60 Suppl 3:S161-S164.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 40]  [Cited by in F6Publishing: 47]  [Article Influence: 5.9]  [Reference Citation Analysis (0)]
12.  Liu Y, Xian Y, Liu X, Cheng Z, Wei S, Wang J, Chen J, Li C, Ma J, Yang J, Liu F, Yu M, Chen Z, Cui Z. Significant insights from a National survey in China: PrEP awareness, willingness, uptake, and adherence among YMSM students. BMC Public Health. 2024;24:1009.  [PubMed]  [DOI]  [Cited in This Article: ]  [Reference Citation Analysis (0)]
13.  Zhang XN, Yan K, You XD, Li JH, Zhang N, Wang GY, Liao MZ, Ma W. [Acceptance of pre-exposure prophylaxis and post-exposure prophylaxis against HIV and related factors in men who have sex with men in Shandong Province]. Zhonghua Liu Xing Bing Xue Za Zhi. 2023;44:1352-1357.  [PubMed]  [DOI]  [Cited in This Article: ]  [Reference Citation Analysis (0)]
14.  Xia DY, Su XL, Liu GW, Ren XL, Wang J, Li GY, Chen J, Xu CH, Lu HY. [HIV infection rate, high-risk behavior and pre-exposure prophylaxis/post-exposure prophylaxis in men who have sex with men in Beijing]. Zhonghua Liu Xing Bing Xue Za Zhi. 2023;44:1390-1396.  [PubMed]  [DOI]  [Cited in This Article: ]  [Reference Citation Analysis (0)]
15.  Tshering K, Wangchuk K, Letho Z. Assessment of knowledge, attitude and practice of post exposure prophylaxis for HIV among nurses at Jigme Dorji Wanghuck National Referral Hospital, Bhutan. PLoS One. 2020;15:e0238069.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 3]  [Cited by in F6Publishing: 6]  [Article Influence: 1.5]  [Reference Citation Analysis (0)]
16.  Anteneh B, Belachew SA, Endeshaw A, Wubneh ZB, Sarkar BR. Knowledge, attitude and practices of medical and health science students on the antiretroviral based HIV post-exposure prophylaxis in an Ethiopian hospital: an institutional based cross-sectional study. BMC Health Serv Res. 2019;19:713.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 5]  [Cited by in F6Publishing: 5]  [Article Influence: 1.0]  [Reference Citation Analysis (0)]
17.  Sun S, Yang C, Zaller N, Zhang Z, Zhang H, Operario D. PrEP Willingness and Adherence Self-Efficacy Among Men Who have Sex with Men with Recent Condomless Anal Sex in Urban China. AIDS Behav. 2021;25:3482-3493.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 6]  [Cited by in F6Publishing: 5]  [Article Influence: 1.7]  [Reference Citation Analysis (0)]
18.  Guo J, Kang W, Liu T, Xu J, Tang H, Lyu F, Zhang G. Analysis of Knowledge Level and Use of Antiretroviral Pre-Exposure and Post-Exposure Prophylaxis Among MSM - China, 2019-2022. China CDC Wkly. 2023;5:292-296.  [PubMed]  [DOI]  [Cited in This Article: ]  [Reference Citation Analysis (0)]
19.  Etowa J, Tharao W, Mbuagbaw L, Baidoobonso S, Hyman I, Obiorah S, Aden M, Etowa EB, Gebremeskel A, Kihembo M, Nelson L, Husbands W. Community perspectives on addressing and responding to HIV-testing, pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) among African, Caribbean and Black (ACB) people in Ontario, Canada. BMC Public Health. 2022;22:913.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 5]  [Reference Citation Analysis (0)]
20.  Zhang C, Fiscella K, Przybylek S, Chang W, Liu Y. Telemedicine Experience for PrEP Care among PrEP-Eligible Women and Their Primary Care Providers during the First Year of the COVID-19 Pandemic in the United States. Trop Med Infect Dis. 2022;7.  [PubMed]  [DOI]  [Cited in This Article: ]  [Reference Citation Analysis (0)]
21.  Anand T, Nitpolprasert C, Trachunthong D, Kerr SJ, Janyam S, Linjongrat D, Hightow-Weidman LB, Phanuphak P, Ananworanich J, Phanuphak N. A novel Online-to-Offline (O2O) model for pre-exposure prophylaxis and HIV testing scale up. J Int AIDS Soc. 2017;20:21326.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 37]  [Cited by in F6Publishing: 40]  [Article Influence: 5.7]  [Reference Citation Analysis (0)]
22.  Irvine C, Egan KJ, Shubber Z, Van Rompay KK, Beanland RL, Ford N. Efficacy of HIV Postexposure Prophylaxis: Systematic Review and Meta-analysis of Nonhuman Primate Studies. Clin Infect Dis. 2015;60 Suppl 3:S165-S169.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 38]  [Cited by in F6Publishing: 40]  [Article Influence: 5.0]  [Reference Citation Analysis (0)]
23.  Wang X, Xu J, Wu Z. A Pilot Program of Pre-Exposure and Post-Exposure Prophylaxis Promotion among Men Who Have Sex with Men - 7 Study Sites, China, 2018-2019. China CDC Wkly. 2020;2:917-919.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2]  [Cited by in F6Publishing: 3]  [Article Influence: 0.8]  [Reference Citation Analysis (0)]
24.  Hou J, Wu Y, Xie L, Meng S, Fu R, Zheng H, He N, Huang X, Xu J, Meyers K. Post-exposure prophylaxis: an underutilized biomedical HIV prevention method among gay, bisexual and other men who have sex with men in China. AIDS Care. 2020;32:1573-1580.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 12]  [Cited by in F6Publishing: 9]  [Article Influence: 2.3]  [Reference Citation Analysis (0)]
25.  Fu Y, Ashuro AA, Feng X, Wang T, Zhang S, Ye D, Fan Y. Willingness to use HIV pre-exposure prophylaxis and associated factors among men who have sex with men in Liuzhou, China. AIDS Res Ther. 2021;18:46.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2]  [Cited by in F6Publishing: 4]  [Article Influence: 1.3]  [Reference Citation Analysis (0)]
26.  Holt M, Lea T, Kippax S, Kolstee J, Ellard J, Velecky M, Murphy D, de Wit J. Awareness and knowledge of HIV pre-exposure prophylaxis among Australian gay and bisexual men: results of a national, online survey. Sex Health. 2016;.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 16]  [Cited by in F6Publishing: 16]  [Article Influence: 2.0]  [Reference Citation Analysis (0)]
27.  Ajayi AI, Mudefi E, Yusuf MS, Adeniyi OV, Rala N, Goon DT. Low awareness and use of pre-exposure prophylaxis among adolescents and young adults in high HIV and sexual violence prevalence settings. Medicine (Baltimore). 2019;98:e17716.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 13]  [Cited by in F6Publishing: 23]  [Article Influence: 4.6]  [Reference Citation Analysis (0)]
28.  Silva KRO, Ferreira RC, Coelho LE, Veloso VG, Grinsztejn B, Torres TS, Luz PM. Knowledge of HIV transmission, prevention strategies and U = U among adult sexual and gender minorities in Brazil. J Int AIDS Soc. 2024;27:e26220.  [PubMed]  [DOI]  [Cited in This Article: ]  [Reference Citation Analysis (0)]
29.  Ferreira RC, Torres TS, Ceccato MDGB, Bezerra DR, Thombs BD, Luz PM, Harel D. Development and Evaluation of Short-Form Measures of the HIV/AIDS Knowledge Assessment Tool Among Sexual and Gender Minorities in Brazil: Cross-sectional Study. JMIR Public Health Surveill. 2022;8:e30676.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1]  [Cited by in F6Publishing: 7]  [Article Influence: 3.5]  [Reference Citation Analysis (0)]
30.  Mimiaga MJ, Case P, Johnson CV, Safren SA, Mayer KH. Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr. 2009;50:77-83.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 174]  [Cited by in F6Publishing: 192]  [Article Influence: 12.8]  [Reference Citation Analysis (0)]
31.  Simões D, Meireles P, Rocha M, Freitas R, Aguiar A, Barros H. Knowledge and Use of PEP and PrEP Among Key Populations Tested in Community Centers in Portugal. Front Public Health. 2021;9:673959.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2]  [Cited by in F6Publishing: 8]  [Article Influence: 2.7]  [Reference Citation Analysis (0)]
32.  Sousa LRM, Elias HC, Fernandes NM, Gir E, Reis RK. Knowledge of PEP and PrEP among people living with HIV/aids in Brazil. BMC Public Health. 2021;21:64.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 7]  [Cited by in F6Publishing: 13]  [Article Influence: 4.3]  [Reference Citation Analysis (0)]
33.  Adal O, Abebe A, Ayele T. Knowledge, attitude, and practice of human immune-deficiency virus (HIV) post-exposure prophylaxis among healthcare workers of governmental hospitals in Addis Ababa, Ethiopia. Infect Prev Pract. 2023;5:100270.  [PubMed]  [DOI]  [Cited in This Article: ]  [Reference Citation Analysis (0)]
34.  Closson K, Chown S, Armstrong HL, Wang L, Bacani N, Ho D, Jollimore J, Olarewaju G, Moore DM, Roth EA, Hogg RS, Lachowsky NJ. HIV leadership programming attendance is associated with PrEP and PEP awareness among young, gay, bisexual, and other men who have sex with men in Vancouver, Canada. BMC Public Health. 2019;19:429.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 4]  [Cited by in F6Publishing: 4]  [Article Influence: 0.8]  [Reference Citation Analysis (0)]
35.  Ayieko J, Petersen ML, Kabami J, Mwangwa F, Opel F, Nyabuti M, Charlebois ED, Peng J, Koss CA, Balzer LB, Chamie G, Bukusi EA, Kamya MR, Havlir DV. Uptake and outcomes of a novel community-based HIV post-exposure prophylaxis (PEP) programme in rural Kenya and Uganda. J Int AIDS Soc. 2021;24:e25670.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 13]  [Cited by in F6Publishing: 9]  [Article Influence: 3.0]  [Reference Citation Analysis (0)]